Here we investigated the effects of chronic treatment with the novel selective OXR-1 antagonist ACT-335827 in a rat model of diet-induced obesity (DIO) associated with metabolic syndrome (MetS). This evidence concerns the gene OXR1 and obesity due to melanocortin 4 receptor deficiency.